Patient ‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

ConclusionNo significant differences in mean or magnitude of change in neurotoxicity scores were observed between treatment arms at any time point. However, patients in the placebo arm reported worsening neurotoxicity from baseline to 3 ‐months (M difference = −1.5,P = .045), compared to stable neurotoxicity in the veliparib arm (M difference = −0.2,P = .778). Weakness was the most common treatment‐emergent (>50%) and moderate to severe (>16%) symptom reported, but did not differ between treatment arms. The proportion of adherence to oral therapy in the overall sample was 75%. Three percent of patients reported clinically significant neurotoxicity that was not captured by physician assessment. Neurotoxicity scores were not different between treatment arms. The addition of veliparib to CE appeared tolerable, though weakness should be monitored.ClinicalTrials.gov IdentifierNCT01642251.

Source: Cancer Medicine - August 27, 2020 Category: Cancer & Oncology Authors: Laurie E. Steffen McLouth, Fengmin Zhao, Taofeek K. Owonikoko, Josephine L. Feliciano, Nisha A. Mohindra, Suzanne E. Dahlberg, James L. Wade, Gordan Srkalovic, Bradley W. Lash, Joseph W. Leach, Ticiana A. Leal, Charu Aggarwal, David Cella, Su Tags: ORIGINAL RESEARCH Source Type: research